Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

ClinicalTrials.gov ID: NCT03614663

Public ClinicalTrials.gov record NCT03614663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome

Study identification

NCT ID: NCT03614663
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Zynerba Pharmaceuticals, Inc.; Industry
Enrollment: 212 participants

Conditions and interventions

Conditions

Fragile X Syndrome

Interventions

ZYN002 - Cannabidiol Transdermal Gel Drug
Placebo Transdermal Gel Other

Drug · Other

Eligibility (public fields only)

Age range: 3 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 11, 2018
Primary completion: Jun 13, 2020
Completion: Jun 13, 2020
Last update posted: Jul 5, 2022

2018 – 2020

United States locations

U.S. sites: 17
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
Southwest Autism Research and Resource Center	Phoenix	Arizona	85006	—
Phoenix Children's Hospital	Phoenix	Arizona	85016	—
UC Davis Health System, MIND Institute	Sacramento	California	95817	—
Children's Hospital of Colorado	Denver	Colorado	80045	—
Emory University School of Medicine	Atlanta	Georgia	30322	—
Rush University Medical Center	Chicago	Illinois	60612	—
Kennedy Krieger Institute	Baltimore	Maryland	21205	—
Boston Children's Hospital	Boston	Massachusetts	02115	—
Fragile X Center of Atlantic Health System	Morristown	New Jersey	07960	—
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics	New York	New York	10029	—
University of North Carolina	Chapel Hill	North Carolina	27510	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	—
Central States Research	Tulsa	Oklahoma	74136	—
Suburban Research Associates	Media	Pennsylvania	19063	—
Greenwood Genetic Center	Greenville	South Carolina	29605	—
University of Washington Center for Human Development and Disability	Seattle	Washington	98198	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03614663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 5, 2022 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03614663 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →